Chemotherapy-resistant metastatic breast cancer

Current Treatment Options in Oncology

Volumn 13, Issue 2, 2012, Pages 263-275

  Marquette, Carrie ^a   Nabell, Lisle ^a  

^a NONE   (United States)

Author keywords

Combinatorial regimens; Microtubulins; Treatment of resistant breast cancer

Indexed keywords

ABC TRANSPORTER; ANGIOGENESIS INHIBITOR; ANTHRACYCLINE DERIVATIVE; CARBOPLATIN; DOCETAXEL; ELACRIDAR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERIBULIN; EVEROLIMUS; EXEMESTANE; GEMCITABINE; IXABEPILONE; LAPATINIB; LAROTAXEL; LETROZOLE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; NAVELBINE; OLAPARIB; PERTUZUMAB; SUNITINIB; TANESPIMYCIN; TARIQUIDAR; TAXANE DERIVATIVE; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; UNINDEXED DRUG; VALSPODAR; VERAPAMIL; VINFLUNINE; ZOSUQUIDAR;

ACUTE LEUKEMIA; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER PATIENT; CANCER RESISTANCE; CANCER STEM CELL; CANCER SURVIVAL; CONSTIPATION; DNA REPAIR; FATIGUE; HUMAN; MONOTHERAPY; MULTIDRUG RESISTANCE; NEUROPATHY; NEUTROPENIA; NONHUMAN; PHENOTYPE; PROGRESSION FREE SURVIVAL; PROTEIN FAMILY; RECURRENT CANCER; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; TUMOR VASCULARIZATION;

EID: 84863715487     PISSN: 15272729     EISSN: 15346277     Source Type: Journal    
DOI: 10.1007/s11864-012-0184-6     Document Type: Article

References (67)

1. Hall MD, Handley MD, Gottesman MM. Is resistance useless? Multidrug resistance and collateral sensitivity. Trend Pharmacol Sci. 2009;30 (10):546-56.
2. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov. 2006;5(3):219-34.
3. Twentyman PR. Cyclosporins as drug resistance modifiers. Biochem Pharmacol. 1992;43:109-17.
4. Cripe LD, Uno H, Paietta EM, et al. Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: A randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999. Blood. 2010;116:4077-85.
5. Ruff P, Vorobiof DA, et al. A randomized, placebocontrolled, double-blind phase 2 study of docetaxel compared to docetaxel plus zosuquidar (LY335979) in women with metastatic or locally recurrent breast cancer who have received one prior chemotherapy regimen. Canc Chemother Pharmacol. 2009;64 (4):763-8.
6. Ferlini C, Raspaglio G, Cicchillitti L, et al. Looking at drug resistance mechanisms for microtubule interacting drugs: Does TUBB3 work? Curr Cancer Drug Targets. 2007;7:704-12.
7. Seve PS, Dumontet C. Is class III β-Tubulin a predictive factor in patients receiving tubulin-binding agents? Lancet Oncol. 2009;9:168-75.
8. Lee FY, Smykla R, Johnston K, et al. Preclinical efficacy spectrum and pharmacokinetics of ixabepilone. Canc Chemother Pharmacol. 2009;63:201-12.
9. Denduuluri N, Swain S. Ixabepilone: Clinical role in metastatic breast cancer. Clin Breast Cancer. 2011;3:139-45.
10. Sparano JA, Vrdoljak E, Rixe O, Xu B, et al. Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. JCO. 2010;28:3256-63.
11. Fornier M, Fumoleau P. The paradox of triple negative breast cancer: Novel approaches to treatment. The Breast Journal 2011; doi: 10.1111/j.1524-4741.2011.01175.x. Provides a succinct overview of approaches to a subgroup of breast cancer that epitomizes the improvements made in defining breast cancer at a molecular level.
12. Jimeno A. Eribulin: Rediscovering tubulin as an anticancer target. Clin Cancer Res. 2009;15:3903-5.
13. Jordan MA, Kamath K, Manna T, et al. The primary antimitotic mechanism of action of the synthetic halichondrins E7389 is suppression of microtubule growth. Mol Cancer Ther. 2005;4:1086-95.
14. Cortes, et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): A phase 3 open-label randomised study Lancet. 2011;377:914-23. One of the newest agents approved for use in the treatment of metastatic breast cancer, this class of drugs demonstrates activity in taxane resistant breast cancer.
15. Ribeiro JT, Macedo LT, Curigliano G, et al. Cytotoxic drugs for patients with breast cancer in the era of targeted treatment: Back to the future? Ann Oncol. 2011. doi:10.1093/annonc/mdr382.
16. Anton Aparicio LM, Pulido EG, Gallego GA. Vinflunine: A new vision that may translate into antiangiogenic and antimetastatic activity. Anticancer Drugs 2012 Jan23(1):1-11.
17. Capone, et al. Vinflunine: A new active drug for second-line treatment of advanced breast cancer. Results of a phase II and pharmacokinetic study in patients progressing after first-line anthracycline/taxane-based chemotherapy. Br J Cancer. 2006;95:1161-6.
18. Fumoleau P, Cortes-Funes H, Taleb AB, Chan S, et al. Phase 2 study of single-Agent IV vinflunine as thirdline treatment of metastatic breast cancer after failure of anthracycline/taxane-based chemotherapy. Am J Clin Oncol. 2009;32(4):375-80.
19. Campone M, Isambert N, Bourbouloux E, et al. A phase I study of vinflunine in combination with capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and taxanes. Canc Chemother Pharmacol. 2011. doi:10.1007/s00280-011-1767-9.
20. Venkitaraman AR. Linking the cellular functions of BRCA genes to cancer pathogenesis and treatment. Annu Rev Pathol. 2009;4:461-87.
21. Rios J, Puhalla S. PARP inhibitors in breast cancer: BRCA and beyond. Oncology. 2011;25(11):1014-25.
22. Rakha EA, Reis-Filho JS, Ellis IO. Basal-like breast cancer: A critical review. J Clin Oncol. 2008;26 (15):2568-81.
23. Tutt A, Robson M, Garber JE, et al. Oral poly(ADPribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: A proof-of-concept trial. Lancet. 2010;376:235-44.
24. Audeh MW, Carmichael J, Penson RT, et al. Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: A proof-of-concept trial. Lancet. 2010;376:245-51.
25. Isakoff SJ, Overmoyer B, Tung NM, et al. A phase II trial of the PARP inhibitor veliparib (ABT888) and temozolomide for metastatic breast cancer. J Clin Oncol. 2010;28(suppl):118s. abstr 1019.
26. Sandhu SK, Wenham RM, Wilding G, et al. First-inhuman trial of a poly(ADP-ribose) polymerase (PARP) inhibitor MK-4827 in advanced cancer patients (pts) with antitumor activity in BRCA-deficient and sporadic ovarian cancers. J Clin Oncol. 2010;28(suppl):233s. abstr 3001.
27. O'Shaughnessy J. A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin in metastatic triple-negative breast cancer. J Clin Oncol. 2011;29(suppl):81s. abstr 1007.
28. Roderiguez AA, Makris A, Wu MF, et al. DNA repair signature is associated with anthracycline response in triple negative breast cancer patients. Breast Cancer Res Treat. 2010;123:189-96.
29. Arteaga CL, Sliwkowski MX, Osborne CK, et al. Treatment of HER2-positive breast cancer: Current status and future perspectives. Nat Rev Clin Oncol. 2011;9(1):16-32.
30. Lee-Hoeflich ST, et al. A central role for HER3 in HER2-Amplified breast cancer: Implications for targeted therapy. Cancer Res. 2008;68:5878-87.
31. Campbell MR, Amin D, Moasser MM. Her3 comes of age: New insights into its functions and role in signaling, tumor biology, and cancer therapy. Clin Cancer Res. 2010;16:1209-18.
32. Bedard PL, de Azambuja E, Cardoso F. Beyond trastuzumab: Overcoming resistance to targeted HER-2 therapy in breast cancer. Curr Cancer Drug Targets. 2009;9(2):148-62.
33. De P, Leyland-Jones B. Whither HER2-related therapeutics? J Clin Oncol. 2010;28(7):1091-6.
34. Agus, DB, Gordon MS, Taylor C, et al. Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. JCO2005:2534-2543.
35. Baselga J, Gelmon KA, Verma S, et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. JCO 2010:1138-1144.
36. LoRusso PM, Weiss D, Guardino E, Girish S, Silwkowski MX. Trastuzumab emtansine: A unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer. Clin Cancer Res. 2011;17 (20):6437-47.
37. Schoeberl B, Faber AC, Li D, et al. An ErbB3 antibody, MM-121, is active in cancer with ligand-dependent activation. Cancer Res. 2010;70(6):2485-94.
38. Arpino G, Weichmann L, Osborne CK, et al. Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family. Endocr Rev. 2008;29:217-33.
39. Johnston S, Pippen Jr J, Pivot X, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol. 2010;27:5538-46.
40. Ghayad SE, Vendrell JA, Larbi SB, et al. Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways. Int J Cancer. 2010;126 (2):545-62.
41. Pandolfi PP. Breast cancer: Loss of PTEN predicts resistance to treatment. N Engl J Med. 2004;351:2337-8.
42. Morrow PK, Wulf GM, Ensor J, et al. Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy. JCO. 2011;29:3126-32.
43. Miller TW, Balko JM, Arteaga CL. Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer. J Clin Oncol. 2011;29:4452-61.
44. Baselga j, Campone M, Sahmoud T, et al. Everolimus in combination with exemestane for postmenopausal women with advanced breast cancer who are refractory to letrozole or anastrozole: Reports of the BOLERO-2 phase III trial. 2011 European Multidisciplinary Cancer Congress. Abstact 9LBA, 2011.
45. Baselga J, Campone M, Piccart M et al. Everolimus in postmenopausal hormone-receptor positive advanced breast cancer. N Engl J Med 2011 Dec (Epub ahead of print). Represents an early success story in the use of combining agents targeting intersecting pathways that are drivers for breast cancer proliferation.
46. Alvarez RH, Guarneri V, et al. Bevacizumab treatment for advanced breast cancer. Oncologist 2011 Dec 6 Epub ahead of print.
47. Valachis A, Polyzos NP, Patsopoulos NA, et al. Bevacizumab in metastatic breast cancer: A meta-Analysis of randomized controlled trials. Breast Cancer Res Treat. 2010;122(1):1-7.
48. Miller KD, O'Neill A, Perez EA, Seidman AD, Sledge GW. A phase II pilot trial incorporating bevacizumab into dose-dense doxorubicin and cyclophosphamide followed by paclitaxel in patients with lymph node positive breast cancer: A trial coordinated by the Eastern Cooperative Oncology Group. Ann Oncol 2011 Aug 4 (Epub ahead of print).
49. Forero-Torres A, Salhe MN, Galleshaw, Jones CF, Shah JJ, Percent IJ, Nabell LM, Carpenter JC, et al. Pilot trial of preoperative (neoadjuvant) letrozole in combination with bevacizumab in postmenopausal women with newly diagnosed estrogen receptor-or progesterone receptor-positive breast cancer. Clin Breast Cancer. 2010;10(4):275-80.
50. Yarkley DA, Burris HA, Clark BL, Shipley D, et al. Hormonal therapy plus bevacizumab in postmenopausal patients who have hormone recepor-positive metastatic breast cancer: A phase II trial of the Sarah Cannon Oncology Research Consortium. Clin Breast Cancer. 2011;11(3):146-52.
51. Crown J, et al. (2010) Phase III trial of sunitinib (SU) in combination with capecitabine (C) versus C in previously treated advanced breast cancer (ABC) J Clin Oncol 28(suppl; abstr LBA1011):18 s.
52. Kerbel RS. Reappraising antiangiogenic therapy for breast cancer.Breast 2011;Suppl3:S56-60.
53. Al-Hajj M, Wicha MS, Benito-Hernandez A, et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 2003;100:3983-8.
54. Charafe-Jauffret E, Ginestier C, Iovino F, et al. Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res. 2009;69:1302-13.
55. Liu S, Wicha MS. Targeting Breast Cancer Stem Cells. J Clin Oncol. 2010;28:4006-12.
56. Korkaya H, Paulson A, Iovino F, et al. HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion. Oncogene. 2008;27:6120-30.
57. Korkaya H, Paulson A, Charafe-Jauffret E, et al. Regulation of mammary stem/progenitor cells by PTEN/Akt/beta-catenin signaling. PLoS Biol. 2009;7:e1000121.
58. Ashkenazi A, Holland P, Eckhardt SG. Ligand-based targeting of apoptosis in cancer: The potential of recombinant human apoptosis ligand 2/tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). JCO. 2008;26:3621-30.
59. Ghobrial IM, Witzig TE, Adjei AA. Targeting apoptosis pathways in cancer therapy. CA Cancer J Clin 2005:178-194.
60. Londono-Joshi AI, Oliver PG, Li Y, et al. Basal-like breast cancer stem cells are sensitive to anti-DR5 mediated cytotoxicity. Breast Cancer Res 2011 Sept (Epub ahead of print).
61. Lee JIY, Huerta-GYepez SH, Vega M, et al. The no trail to yes trail in cancer therapy (review). Int J of Oncology. 2007;31:685-91.
62. Garimella SV, Rocca A, Lipkowitz S. WEE1 inhibition sensitizes basal breast cancer cells to TRAIL-induced apoptosis. Mol Cancer Res 2011 Dec 20 (Epub ahead of print).
63. Piggott, L, Omidvar N, Perez SM, et al. Suppression of apotosis inhibitor c-FLIP selectively eliminates breast cancer cell activity in response to the anticancer agent, TRAIL. Breast Cancer Res 2011;13(5):
64. Rahman M, Davis SR, Pumphrey JG, et al. TRAIL induces apoptosis in triple-negative breast cancer cells with a mesenchymal phenotype. Breast Cancer Res Treat. 2009;113:217-30.
65. Forero-Torres A, Shah J, Wood T, Posey J, et al. Phase I trial of weekly tigatuzumab, an agonistic humanized monoclonal antibody targeting death receptor 5 (DR5). Cancer Biother Radiopharm. 2010;1:13-9.
66. Barginear MF, v Poznak C, Rosen N, et al. The heat shock protein 90 chaperone complex: An evolving therapeutic target. Curr Cancer Drug Targets. 2008;6:522-32.
67. Modi S, Stopeck A, Linden H, et al. HSP90 inhibition is effective in breast cancer: A phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab. Clin Cancer Res. 2011;17 (15):5132-9.